Blog
Using CANTAB to enhance pro-cognitive clinical trials in multiple sclerosis
Accurate outcome measures and suitable patient recruitment will be vital to the success of pro-cognitive treatment trials in multiple sclerosis (MS). In this article, we highlight the sensitivity of various CANTAB tasks to cognitive dysfunction in MS, and discuss the advantages of using these computerised assessments over paper-and-pencil based tests. We also consider how CANTAB tasks can be used to screen prospective participants for specific types and severities of cognitive impairment in order to gauge their suitability for inclusion in pro-cognitive intervention trials.
Three ways you can design better drug trials for schizophrenia therapeutics
To date, no effective drugs have been developed to address cognitive dysfunction in schizophrenia. Here we will highlight the three main methodological challenges which may be contributing to these high failure rates, and propose potential practical solutions to these problems.
Exploring participant-level trajectories of cognitive performance in patients with schizophrenia
Cambridge Cognition and Boehringer Ingelheim have been investigating cognitive performance among patients with schizophrenia, with a view to improving future pro-cognitive drug trial designs. Our Director of Neuroscience, Dr Kiri Granger, presented the latest findings at ISCTM and SIRS.
Can acetylcholinesterase inhibitors and CNS stimulants tackle cognitive dysfunction in multiple scle
Cognitive dysfunction in multiple sclerosis (MS) presents a significant, unmet therapeutic need. Researchers at Cambridge Cognition and the University of Manchester investigated potential solutions to this problem with a systematic review and meta-analysis of pro-cognitive drug trials in MS.
Patient recruitment: are you selecting the right patients for schizophrenia clinical trials?
The importance of recruiting patients for pro-cognitive drug trials in schizophrenia on the basis of cognitive dysfunction.
Improving clinical trials for pro-cognitive drugs in schizophrenia
Introducing a blog-post series to discuss key limitations, and potential improvements, for pro-cognitive drug trials in schizophrenia.
The benefits of language and culture independent touchscreen cognitive tests
When assessing cognitive function, tests that are reliable, time and cost efficient and are comparable across cultures and languages are the key to producing accurate and valid results. There are various cognitive assessment tools out there, but what are the benefits of using language and culture independent touchscreen tests such as CANTAB?
